At 7.5% CAGR, North America Hyperpigmentation Disorder Treatment Market is Projected to be worth US$ 3,028.73 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the North America hyperpigmentation disorder treatment market was valued at US$ 1,694.83 million in 2022 and is projected to reach US$ 3,028.73 million by 2030, registering a CAGR of 7.5% from 2022 to 2030. Rise in prevalence of melasma and novel products based on PATH-3 technology are among the critical factors attributed to drive the North America hyperpigmentation disorder treatment market growth.

ALASTIN has formulated the PATH-3 technology and validated it through gene expression and cellular models to counteract the pigmentary pathways. This technology helps prevent the recurrence of surface pigmentation and provides protection against future damage due to continued use. The PATH-3 technology also complements in-office treatments, including lasers, skin brightening treatments, and chemical peels. The lightweight, elegant, non-irritating serum used in PATH-3 is formulated without retinol or hydroquinone and is safe for long-term daily use. A novel topical product enabled by the PATH-3 technology has been proven effective and safe in treating facial dyschromia. In October 2022, Galderma launched ALASTIN Skincare A-LUMINATE BRIGHTENING SERUM based on PATH-3 Technology. The new product addition to the ALASTIN Skincare lineup is designed to help lower the appearance of surface hyperpigmentation without any irritating, harsh ingredients. Thus, novel products enabled by the PATH-3 technology are expected to emerge as new trends in the hyperpigmentation disorder treatment market during the forecast period.

On the contrary, the high cost of treatments hampers the growth of the North America hyperpigmentation disorder treatment market.

Based on treatment type, the North America hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held 42.8% market share in 2022, amassing US$ 725.89 million. It is projected to garner US$ 1,344.66 million by 2030 to register 8.0% CAGR during 2022–2030.

Based on condition, the North America hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held 47.1% market share in 2022, amassing US$ 797.58 million. It is projected to garner US$ 1,463.04 million by 2030 to register 7.9% CAGR during 2022–2030.

Based on end user, the North America hyperpigmentation disorder treatment market is segmented into hospitals, dermatology centers, and others. The hospitals segment held 48.1% market share in 2022, amassing US$ 815.00 million. It is projected to garner US$ 1,446.85 million by 2030 to register 7.4% CAGR during 2022–2030.

Based on country, the North America hyperpigmentation disorder treatment market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 62.5% share of North America hyperpigmentation disorder treatment market in 2022. It was assessed at US$ 1,058.71 million in 2022 and is likely to hit US$ 1,908.67 million by 2030, registering a CAGR of 7.6% during 2022–2030.

Key players operating in the North America hyperpigmentation disorder treatment market are AbbVie Inc, Bayer AG, Galderma SA, L’OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Vivier Pharma Inc, among others.

• In February 2024, L'Oréal Paris launched the Glycolic Bright Dark Circle Eye Serum, a groundbreaking solution for under-eye hyperpigmentation and puffiness. The serum, formulated with a blend of 3 percent Glycolic Acid, Vitamin CG, and Niacinamide, promises to diminish dark circles by -49% in just two weeks. The serum is priced at Rs 699 and is ophthalmologically tested, suitable for all skin types, and clinically proven to treat visible dark circles.
• In January 2023, Allergan Aesthetics, a subsidiary of AbbVie company, launched SkinMedica Even & Correct Collection. These three products - Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads are formulated to deliver targeted results and work together to even skin tone and reduce the appearance of hyperpigmentation and dark spots on the face.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com